Avenue Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 7 - Net Loss Per Share

Note 7 - Net Loss Per Share

9 Months Ended

Sep. 30, 2023

Note 7 - Net Loss per Share

Loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding, excluding unvested restricted stock and stock options and preferred shares, during the period. Dividends declared are paid and set aside among the holders of shares of common stock and Class A Preferred stock pro-rata on an as-if-converted basis.

The following table sets forth the potential common shares that could potentially dilute basic income per share in the future that were not included in the computation of diluted net loss per share because to do so would have been anti-dilutive for the periods presented:

	*For the Three and Nine Months Ended*
	*September 30,*
	*2023*		*2022*
Unvested restricted stock units/awards		98,137		13,145
Warrants		6,078,132		—
Options		1,685,000		—
Class A Preferred shares		16,666		16,666
Total potential dilutive effect		7,877,935		29,811